The role of the C-terminal domain of CTP: phosphocholine cytidylyltransferase (CT) was explored by the creation of a series of deletion mutations in rat liver cDNA, which were expressed in COS cells as a major protein component. Deletion of up to 55 amino acids from the C-terminus had no effect on the activity of the enzyme, its stimulation by lipid vesicles or on its intracellular distribution between soluble and membrane-bound forms. However, deletion of the C-terminal 139 amino acids resulted in a 90 % decrease in activity, loss of response to lipid vesicles and a significant decrease in the fraction of membrane-bound enzyme. Identification of the domain that is phosphorylated in vivo was determined by analysis of 32P-labelled CT mutants and by chymotrypsin proteolysis of purified CT that was 32P-labelled in vivo. Phosphorylation was restricted to the C-terminal 52 amino acids (domain P) and occurred on multiple sites. CT phosphorylation in vitro was catalysed by casein kinase II, cell division INTRODUCTION
INTRODUCTION
CTP: phosphocholine cytidylyltransferase (CT) is an important regulatory enzyme of the phosphatidylcholine metabolic cycle [1] , which, under most conditions, controls the rate of phosphatidylcholine (PC) synthesis by interconversion between an inactive soluble form and an active membrane-bound form [2, 3] . The soluble form appears to be stabilized by phosphorylation at specific sites, whereas the active form is stabilized by interaction with lipids [4] [5] [6] . Translocation from a soluble form to membranes is associated with dephosphorylation, while the reverse process is accompanied by phosphorylation [6] [7] [8] [9] [10] . During the cell cycle of a macrophage cell line, Bac-1, the degree of phosphorylation of CT varied in concert with changes in enzyme activity [11] . The lipid interaction depends on the presence within the membrane of certain lipid activator molecules, such as anionic phospholipids, fatty acids or diacylglycerol [12] .
The primary structures of several mammalian CTs [13] [14] [15] [16] [17] [18] and CT from Saccharomyces cerevisiae [19] have been determined. The mammalian CTs are highly conserved with > 96 % identity at the amino acid level. Secondary structure predictions suggest a tripartite organization: (1) a globular N-terminal domain (residues 1-235); (2) a pair of amphipathic a-helices (residues 236-315); and (3) a C-terminus dominated by turns (residues 316-367). This basic structure is supported by limited proteolysis, control 2 kinase (cdc2 kinase), protein kinases Ca and /3ll, and glycogen synthase kinase-3 (GSK-3), but not by mitogen-activated kinase (MAP kinase). Casein kinase II phosphorylation was directed exclusively to Ser-362. The sites phosphorylated by cdc2 kinase and GSK-3 were restricted to several serines within three proline-rich motifs of domain P. Sites phosphorylated in vitro by protein kinase C, on the other hand, were distributed over the N-terminal catalytic as well as the C-terminal regulatory domain. The stoichiometry of phosphorylation catalysed by any of these kinases was less than 0.2 mol P/mol CT, and no effects on enzyme activity were detected. This study supports a tripartite structure for CT with an N-terminal catalytic domain and a Cterminal regulatory domain comprised of a membrane-binding domain (domain M) and a phosphorylation domain (domain P). It also identifies three kinases as potential regulators in vivo of CT, casein kinase II, cyclin-dependent kinase and GSK-3.
which shows that the N-terminal two-thirds is more resistant to digestion than the C-terminal one-third [20] .
The structure and function of the N-terminal 75 residues is relatively unexplored. CT appears, by immunofluorescence, to be a nuclear enzyme [21] . Deletion of a polybasic site (residues 12-16) alters the nuclear localization of the enzyme [22] . The domain between amino acids 75 and 235 is highly conserved between the yeast and mammalian CTs and is believed to house the active site [13, 23, 24] . There is now strong evidence that amino acids 239-298 function in membrane binding. This region constitutes a discrete exon in the mouse CT gene [16] . Synthetic peptides from this region were transformed from random coil to a-helix in the presence of anionic lipid vesicles and intercalated into the hydrophobic core of these vesicles [25] . Furthermore, loss of membrane binding directly correlated with loss of the amphipathic helix when residues from the C-terminus were progressively removed using limited proteolysis [20] .
C-Terminal to the lipid-binding amphipathic helix there is a short domain (17 residues) of unknown function,-which is predicted to be helical. The C-terminal 55 amino acids contain 16 serines which fall within substrate consensus sequences for several protein kinases. Phosphopeptide analysis of 32P-labelled CT immunoprecipitated from several sources [6, 8, 10, 26] has shown that mammalian CT is phosphorylated on multiple sites. CT from cell extracts is often visualized on SDS gels as a set of two Abbreviations used: CT, CTP: phosphocholine cytidylyltransferase; PKC, protein kinase C; MAP kinase, mitogen-activated kinase; GSK-3, glycogen synthase kinase-3; cdc2 kinase, cell division control 2 kinase; PC, phosphatidylcholine; DAG, diacylglycerol; PG, phosphatidylglycerol; CSF-1, colonystimulating factor-1; DTT, dithiothreitol; EGF, epidermal growth factor; TBS, Tris-buffered saline; PAP, potato acid phosphatase.
§ To whom correspondence should be addressed. 699 700 R. B. Cornell and others or three bands between 42 and 44 kDa, which is also indicative of multiple phosphorylated forms [6, 11] . Recently MacDonald and Kent [26] demonstrated that the C-terminal 55 residues constitute the sole site of phosphorylation in vivo, and that all 16 serines in this domain are phosphorylated to some extent in rat liver CT, which was overexpressed using baculovirus and purified from insect cells. The phosphorylation domain is very rich in prolines. At least seven serines are candidates for phosphorylation by mitogenactivated kinases (MAP kinases) [27] or cyclin-dependent kinases [28] . Ser-362 resides within an acidic context (DISEDEED) that resembles the target site for casein kinase II [28] . There is also the potential for phosphorylation by glycogen synthase kinase-3 (GSK-3) on several sites in the proline-rich region, in response to phosphorylation on downstream sites by other kinases [29, 30] . Up to ten potential protein kinase C (PKC) sites are dispersed throughout the N-and C-terminal domains of CT. Treatment with phorbol esters, however, did not result in detectable changes in the phosphorylation state of CT [31, 32] . Recently Wieprecht et al. [33] reported that CT was a substrate for phosphorylation in vitro, catalysed by p44mPk.
To probe the role of the C-terminal lipid-binding and phosphorylation domains we have constructed mutations in the rat liver CT cDNA, deleting up to 140 amino acids from the Cterminus. In addition, Ser-362 was mutated to alanine. These mutants were expressed in COS cells. We also analysed chymotryptic fragments of wild-type CT, which lacked portions of the C-terminus. Our results show that the C-terminal domain P (Figure 1) is not necessary for enzyme activity, but is required for phosphorylation in vivo and for phosphorylation in vitro by casein kinase II, cell division control 2 kinase (cdc2 kinase) and GSK-3.
MATERIALS AND METHODS Materials
Purified PKCa and PKCflII were generous gifts from Dr. A.
Newton (University of California, San Diego), and purified GSK-3,J was kindly provided by Dr. J. Woodgett (Ontario Cancer Institute, Toronto, Ontario, Canada). All three kinases were recombinant, rat brain-and baculovirus-expressed. Casein kinase II, cdc2 kinase and MAP kinase were purified from sea star as described [34, 35] . Potato acid phosphatase (PAP) was from Boehringer. Heparin, heparin-Sepharose, digitonin, cyanogen bromide-activated Sepharose, peroxidase-antibody conjugate, ATP, CTP, ,-glycerophosphate, dithiothreitol (DTT) and oleic acid were from Sigma. Dioleoyl phosphatidylserine, dioleoyl phosphatidylglycerol (PG) and egg PC were from Avanti. 1,2-Di-oleoylglycerol was generated from egg PC [36] 
Methods

Construction of mutants
The construction of CT-2 (wild-type rat liver CT) from CT-I has been described by Walkey et al. [37] . CT-1 is the original rat liver clone [13] containing two nucleotide mutations that encode for the replacement of Gly-91 with serine and of Ser-1 14 with cysteine. All mutations in this paper contained the wild-type sequence at amino acids 91 and 114. The start codon begins at nucleotide 25 in all CT-2 constructs.
To generate mutants A228 and A312, the CT-2 cDNA in pAX142, a derivative ofpAXl 14 [38] which utilizes an elongation factor-za promoter [39] , was digested with SstI at nucleotide 708 and HaeIII at nucleotide 961 respectively. The A336 mutant was generated using the exonuclease Bal31 according to the manufacturer's instructions (Gibco/BRL), which digested from the 3'-end to nucleotide 1033. The cDNAs were ligated into a pUCderived vector, pEND, which has three stop codons in each of three frames within several nucleotides downstream of the cDNA insertion site. There were up to four additional amino acids appended to the C-termini of the truncated CT sequences (see Figure 1 ). The mutant CT cDNAs were transferred back to pAX142 for sequencing to confirm the mutation and for expression in COS cells.
To generate the A349 mutant, we amplified the rat CT-2 cDNA by PCR in a CTV3 retroviral vector [40] , using a vector specific 5' primer and the 3' CT-specific mutagenic primer: 5'-GCGTCGACTCAAGCTGCTGGGGAGGAAGATGG-GGA-3'. The PCR product was digested with SstI and SalI and the 368 bp fragment was ligated with the 810 bp MluI-SstI fragment of pAX142-CT-2 and MluI-SalI-digested pAX142. This mutant terminates at Ala-349 and contains one additional alanine before the stop codon.
The S362AA site-specific mutation was generated by PCR amplification of pAX142-CT-2 using the mutating primer 5'-GGGGATCCTTAGTCCTCTTCATCCTCGGCGATG-3', and a 5' primer RCT-l [13] . The PCR product was cleaved at the SstI site and ligated into SstI-BamHI-digested pAX142-CT-2. All mutant constructs were confirmed by DNA sequencing.
Transfection and extraction of CT from COS cells COS cells were transfected as previously described [20, 37, 41] , except that the cells were harvested 48 h after transfection and were not subcultured after transfection. Homogenates, cytosol and microsomes were prepared as described [20, 37] . Potassium phosphate was added to 0.2 M after homogenization. CT activity was determined as described [42] .
Digitonin permeabilization Transfected COS cells were permeabilized at 0-2°C as follows. The cells were washed three times with PBS and incubated for 12 min with permeabilization buffer: 0.5 mg/ml digitonin in 20 mM Tris/HCl, pH 7.4, 0.13 M KCI, 3 mM MgCl2, 1 mM PMSF, 2 mM DTT and 60 mM fl-glycerol phosphate. The digitonin lysate was transferred to a cold tube. The cell ghosts were collected by scraping into permeabilization buffer without digitonin. Enzyme activity controls for permeabilization were the cytosolic enzyme lactate dehydrogenase [43] , 90 % of which was in the lysate after 12 min, and the microsomal enzyme cholinephosphotransferase [44] , which was not released after 12 In some experiments using pure CT, chymotrypsin (protease: CT, 1:20 w/w) was added during the last 5 min of the incubation with kinases. The digestion was quenched with 2 mM PMSF followed within 1 min by Laemmli sample buffer and boiling.
Labelling with 32P in vivo At 42-44 h after transfection, COS cells were washed three times with phosphate-free DMEM and labelled for 4 h with the same medium containing 0.1-0.2 mCi/ml [32P]orthophosphate. The cells were harvested as described [41] and were homogenized in buffer A [16] containing 50 mM ,-glycerolphosphate to inhibit phosphatases. In some experiments CT was purified up to the octylglucoside solubilization step [16] . The purity of the CT was 80-90 %, based on densitometry of Coomassie-Blue-stained gels.
Baculovirus-mediated expression and purification of CT CT was purified from the baculovirus expression system [16] with some modifications: T. ni cells (Invitrogen) were initially cultured in T-75 flasks in Grace's medium supplemented with 10% fetal bovine serum. Before infection with recombinant baculovirus containing rat liver CT cDNA (a gift from Dr. C. Kent), cells were transferred to three 100-ml spinner bottles. After reaching a density of 1.5 x 106 cells/ml, cells were resuspended in SF-900 medium and inoculated with virus at 30 x 108plaque-forming units/100 ml (multiplicity of infection = 20) and were harvested 65-70 h later. The subsequent protocol followed that of MacDonald and Kent [16] with the following minor modifications: the eluant from the DEAE-Sepharose column was diluted 2.5-fold before loading onto the hydroxylapatite column; the Triton X-100 concentration in the final eluant from this column was 0.05 %.
Electrophoresis, autoradiography, quantification of radioactivity of bands on gels and Western blotting Proteins were separated using 11, 12 or 13 % acrylamide/SDS gels [45] . Autoradiography of 32P-labelled proteins on dried gels utilized reflectance film (Dupont/NEN) with or without screen, depending on the degree of labelling. Radioactivity in bands was quantified by liquid-scintillation counting of the excised bands, or with the use of a BioRad GS-250 phosphorimager. Protein mass associated with CT bands was quantified using a Microtek Scanmaker densitometer and NIH image software. For some experiments using purified wild-type CT, the density of the Coomassie Blue-stained CT bands was normalized to 1 [20] .
RESULTS
Expression and activity of C-terminal mutants in COS cells
A diagram of the mutants constructed from the wild-type rat liver CT cDNA is shown in Figure 1 The activities of the C-terminal mutants are shown in Table 1 . Neither substitution of Ser-362 with alanine nor deletion of the final 18, 31 or 55 residues had an effect on the activity of CT in the presence or absence of activating vesicles (PC: oleic acid, 1: 1) using a standard assay [45] . These mutants all contain the complete amphipathic helix domain of CT (see Figure 1 ) and were stimulated 3-4-fold by anionic lipid vesicles (Table 1) . On the other hand, the mutant missing the last 140 amino acids, including the amphipathic helix and eight residues of the conserved domain, had less than 10 % of the catalytic activity of the wild type in the presence of PC-oleic acid vesicles. The activity of this mutant (A228) was not influenced by lipid vesicles composed of PC-oleic acid (1:1) ( [20, 25, 46] . each of the mutants were labelled with [32P]orthophosphate and the degree of labelling was measured after gel electrophoresis of homogenates or cytosol. CT was the major phosphoprotein visible in the COS cell extracts (Figure 3 ). The amount of 32P associated with the CT band decreased with progressive deletion of the C-terminus (Figure 3) . The radioactivity associated with each CT band was examined using four separate gels from two independent labelling experiments. Substitution of Ser-362 with alanine resulted in a 21 + 60'/ reduction in label; deletion of the C-terminal 18 or 31 amino acids yielded a 26 + 14 % or 41 + 6%h reduction in 32P label respectively, and deletion of the C-terminal 55 amino acids eliminated all 32p label. This result suggests that the C-terminal 55 amino acids constitute the sole phosphorylation domain in CT and that there are multiple sites of phosphorylation. These findings are in agreement with previous analysis of Coomassie Blue stain the in vivo phosphorylation sites of rat liver CT expressed in insect cells [26] . In another approach, the in vivo phosphorylation domain was identified using chymotrypsin proteolysis of wild-type CT [20] . After 32P-labelling in vivo, CT was partially purified from COS cells up to the octylglucoside solubilization step [16] . Chymotrypsin digestion generated fragments of 40, 39, 35 and 28 kDa and a faint set of fragments of between 16 and 19 kDa (Figure 4 , lane 2). All the fragments greater than 20 kDa reacted with an antibody against an N-terminal peptide, but not with an anti-Cterminal antibody (Figure 4, lanes 2, 5 and 7) . The antibody against the C-terminal peptide reacted only with the 19 kDa fragment, in addition to the undigested 42 (Figure 4, lanes 8 and 9) Figure Sd, lanes 8 and  9) . This suggested that multiple sites were phosphorylated by cdc2 kinase between residues 312 and the C-terminus.
When GSK-3 was added, no phosphorylation above endogenous levels was observed even for wild-type CT ( Figure Se) . As described below, this absence of phosphorylation of CT by GSK-3 was due to inhibitory factors in the COS cell extract rather than the lack of phosphorylation sites for this kinase.
When PKC,fII was added, we observed phosphorylation not only of wild-type S362AA and A336, but also of the A312 and A228 mutants (Figure 5f ). Quantification of the 32P-labelled CT bands suggested that -50 % of the PKC-catalysed phosphorylation was directed towards the N-terminal domain (A228 mutant; Figure 5f , lane 6). Similar results were obtained using PKCo..
Phosphorylation in vitro of purified wild-type CT
CT was purified to homogeneity from insect cells overexpressing CT via the baculovirus system. Phosphorylation of purified CT was achieved using casein kinase II, cdc2 kinase, PKC or GSK-3, but not MAP kinase. GSK-3-catalysed phosphorylation resulted in a gel shift. Approximately 20 % of the radioactivity was associated with a 43 kDa band ( Figure 6, lane 3) , whereas by Coomassie Blue staining, only the 42 kDa band was readily visible (lane 1). Thus GSK-3 catalyses the hyperphosphorylation of a small fraction of the CT population. cdc2 kinase-catalysed phosphorylation also produced diffuse labelling in the [42] [43] [44] kDa region (lane 7). No -43 kDa phosphoprotein was observed when the reactions contained the kinase but lacked CT (not shown), indicating that this species does not represent phosphorylation of the cyclin B subunit of cdc2 kinase. The phosphorylated CT was digested briefly with chymotrypsin to determine the domain labelled in vitro. When CT phosphorylation was catalysed by GSK-3, the undigested 42 kDa band, the 40 and 39 kDa fragments and three species of -16, 17.5 and 19 kDa were labelled with approximately equal intensity, but the 28 kDa band was not labelled (Figure 6, lane 4) . On the other hand, PKC,II-catalysed phosphorylation resulted in strong labelling of the 28 kDa band, along with the 42, 40, 39 and 35 kDa fragments, and no labelling of the bands of < 20 kDa ( Figure 6, lane 5) . Digestion of CT after phosphorylation using PKCa resulted in labelling of all the C-terminal and N-terminal fragments (results not shown). When CT phosphorylation was catalysed by casein kinase II only the undigested 42 kDa band and a fragment of -19 kDa were labelled ( Figure 6, lane 6) . cdc2 kinase-catalysed phosphorylation strongly labelled the 42 kDa parent species and the -19 kDa fragment and faintly labelled the fragments at 40, 39 and -17.5 kDa (Figure 6, lane  7) . These results suggest that phosphorylation catalysed by casein kinase II, cdc2 kinase and GSK-3 is directed exclusively to the C-terminal domain, while that of PKC-/3II is directed primarily against sites in the N-terminal 28 kDa segment.
To determine why GSK-3 was active towards pure CT, but not towards the CT in COS cell homogenates, we added COS cell homogenate to purified CT and phosphorylated in the presence of GSK-3. The addition of 25 jug of homogenate completely inhibited GSK-3 activity towards 2,tg of pure CT substrate (results not shown). This suggests an inhibitory component in the crude cell homogenate. On the other hand, CT phosphorylation by MAP kinase was negligible using pure CT (not shown) or COS extracts ( Figure Sc) . Inclusion of COS cell homogenate or purified CT reduced the activity of MAP kinase towards myelin basic protein by only -50 %.
The stoichiometries of phosphorylations catalysed by PKCa, cdc2 kinase, casein kinase II and GSK-3 were in the range 0.1-0.2 mol phosphate/mol CT monomer. Samples were removed from these same phosphorylation reactions to assay CT enzyme activity in the presence or absence of saturating levels of lipid-activating vesicles (0.5 mM egg PC: oleic acid, 1:1). Phosphorylated CT was compared with controls not containing kinase. The small increase in the kinase-catalysed phosphorylation state of CT produced no significant changes in CT activity, assayed in the presence or absence of lipid (results not shown). Apparently the purified CT is in a relatively highly phosphorylated form when extracted from cells, even though the purification was carried out in the absence of phosphatase inhibitors.
Treatment of pure CT with PAP linked to Sepharose was effective at removing covalently bound phosphate (70 to > 90 % reduction in c.p.m. of 32p). However, the dephosphorylated CT self-aggregated and/or aggregated with the PAP-Sepharose such that it sedimented at very low g force. The activity of the aggregated, dephosphorylated CT was reduced -70 % and was recalcitrant to rephosphorylation by cdc2 kinase and casein kinase II (results not shown). 
DISCUSSION
Domain M, but not domain P, is required for enzyme activity, lipid responsiveness and lntracellular localization Domain M refers to the 62-residue amphipathic helix between Lys-238 and Leu-299, and domain P refers to the C-terminal 53 amino acids of CT. That domain P is not required for enzyme activity is supported by the lack of effect on catalytic activity of deletion of up to 55 residues. Since the expression levels of wildtype and C-terminal-deletion mutants were equivalent, specificactivity measurements in COS cell extracts from wild-type and mutant CT transfections could be directly compared. None of the deletion mutants lacking portions or all of domain P were affected with respect to maximum catalytic activity. They were also activated 3-to 4-fold by PC-oleic acid vesicles and other lipids that stimulate the wild-type CT.
On the other hand, the mutant missing the C-terminal 139 amino acids (domains M + P) was characterized by large reductions in activity, responsiveness to lipid activators and localization in the membranes. In addition to domains M and P, this mutant lacks eight residues of the conserved domain, which is postulated to contain the catalytic site. This latter factor may be the reason for the low activity. The loss of lipid responsiveness and membrane localization of the A228 mutant is compatible with the idea that the amphipathic helix is responsible for membrane binding and is the principal determinant of the distribution between soluble and membrane-bound forms.
Much data suggests that the phosphorylation state of CT influences membrane association. For example, okadaic acid treatment elevates the degree of phosphorylation and lowers the proportion of membrane-bound CT [6, 10] . Fatty acid or phospholipase C treatment of cells [6] [7] [8] or choline deprivation [9] decreases the phosphorylation state and increases the proportion of membrane-bound CT. On the other hand, kinetic analysis of translocation in reponse to oleic acid or phospholipase C revealed that CT binds to cell membranes in its phosphorylated form and is only subsequently dephosphorylated [8] . Moreover, cholecystokinin stimulates CT dephosphorylation but does not alter its intracellular distribution [47] . We observed that deletion of the entire phosphorylation domain did not change the equilibrium between soluble and membrane-bound forms. Absence of the entire phosphorylation domain is quite different from retention in a dephosphorylated form. When domain P is missing, the membrane affinity may be dictated solely by domain M. When the protein contains a complete M + P regulatory domain, membrane affinity may be dictated by domain M as well as the degree of phosphorylation of domain P: the fewer sites phosphorylated, the more hydrophobic the protein. Our preliminary experiments showing that dephosphorylation of CT decreases its solubility support this hypothesis. To understand how domain P might fine-tune membrane affinity, characterization of its interactions with domain M and the catalytic domain will be needed.
Phosphorylation in vivo is restricted to the C-terminus Our 32P-labelling, in vivo, of a mammalian cell expressing CT, confirms the findings using an insect cell expression system [26] that all the phosphorylation sites are restricted to the C-terminal 53 between the rat liver CT and a CT clone from human K562 cells [14] and thus may be of lesser regulatory importance.
Chymotrypsin digestion of in vivo 32P-labelled CT generated a set of 32P-labelled fragments of < 20 kDa, which have been 
Identfflcation of putative kinases directed towards CT
The C-terminus of CT contains potential sites for phosphorylation by casein kinase II, MAP kinase, cdc2 kinase, GSK-3 and PKC ( Figure 7 ). All of these kinases catalyse the phosphorylation of CT in vitro, except MAP kinase.
Casein kinase 11
Casein kinase II is a ubiquitous kinase that is translocated to the nucleus in response to mitogens [48, 49] and has many nuclear targets such as Max, Myc, Myb, RNA polymerase I and II, nucleolar protein B23 and DNA topoisomerase I and II. Regu- lation of CT by casein kinase II is a reasonable prospect in light of the evidence that CT is a nuclear enzyme [21, 22] and its phosphorylation state changes in response to colony-stimulating factor-I (CSF-1) [11] , insulin, or epidermal growth factor [33] . There are potential casein kinase II sites at Thr-25, Ser-47 and Ser-178. However, only the C-terminal site, Ser-362, was targeted, as evidenced by the complete loss of casein kinase II-catalysed phosphorylation upon substitution of Ser-362 with alanine and also by the lack of phosphorylation of any of the chymotryptic fragments other than that containing the C-terminus. The fidelity of the phosphorylation in vitro to the one acidic site that is phosphorylated in vivo offers some reason to believe that casein kinase II phosphorylation of CT is functionally relevant. Casein kinase II appears to be the dominant kinase activity in COS cell extracts that is directed against CT. This conclusion is based on the response of the endogenous COS cell kinase activity to heparin and on the nearly complete loss of phosphorylation of CT by the endogenous kinase upon substitution of Ser-362.
Removal of the single serine at the 362 site results in a 20 % decrease in the phospho-labelling of CT in vivo. Since aU 16 serines C-terminal of Ile-314 are likely to be phosphorylated to some extent [26] , this result suggests that, (1) the casein kinase II site is a predominant site, or (2) phosphorylation of Ser-362 is required for phosphorylation of some other upstream sites.
707
Phosphorylation at the casein kinase II site had no effect on enzyme activity. Sweitzer and Kent [17] found that a S362AA mutation had no effect on enzyme activity and that this mutant could restore the CDP-choline pathway when transfected into a CHO mutant defective in CT. PKC Four potential sites for PKC-catalysed phosphorylation are found in domain P and up to six are found in the N-terminal domain. Analysis of PKC-catalysed phosphorylation of deletion mutants in COS cell extracts suggested that, in vitro, PKCa and PKC/iII phosphorylated both N-terminal and C-terminal sites. Analysis of chymotrypsin fragments from wild-type CT phosphorylated in the presence of PKCoc or PKCflII suggested targeting of N-terminal sites, primarily. The lack of restriction of PKC action in vitro to domain P suggests a lack of relevance to phosphorylation of CT in vivo. At best 0.2 mol of phosphate was incorporated per mol of CT monomer and this level of phosphorylation did not alter CT activity.
MAP kinase
We were unable to achieve MAP-kinase-catalysed phosphorylation using COS cell extracts or purified CT. The MAP kinase was from sea star, but the consensus phosphorylation sequence is highly conserved and the specific activity towards myelin basic protein was 0.3 ,umol/min per mg and was only partially inhibited by components in the CT preparations. Either CT is not a substrate for MAP kinase or all of the potential sites were completely occupied in the CT extracted from COS or T. ni insect cells. Wieprecht et al. [33] recently reported that phosphorylation of purified CT could be catalysed by MAP kinase, but only after treatment with a crude alkaline phosphatase-agarose from Sigma. The stoichiometry obtained was 0.15 mol P/mol CT. We were unable to dephosphorylate CT using purified alkaline phosphatase from Boehringer. After complete dephosphorylation using acid phosphatase, aggregation of CT prevented rephosphorylation catalysed by MAP kinase or any other kinase. cdc2 kinase The phosphorylation state of CT varies-during the cell cycle [11] . In CSF-1-dependent Bac-l cells the enzyme is dephosphorylated in early G1 phase. Phosphorylation steadily increases during late G1 and continues through the cell cycle, dropping dramatically after mitosis. The peak of the enzyme activity corresponds to the dephosphorylated state in G1. Regulation by cyclin-dependent kinases was proposed to account for these cell-cycle-dependent variations in CT phosphorylation [11] . We found that CT functioned as a substrate for cdc2 kinase in vitro and could be hyperphosphorylated, resulting in a retarded mobility on gels. CT participates in the control of the PC metabolic cycle in which degradation of PC by phospholipases is closely coupled to PC synthesis [1, 3, 37] . Activation of CT could result in increased utilization of DAG or other lipid signalling molecules released via the action of signal-regulated phospholipases. Inhibition of CT activity by cyclin-dependent kinases in late G1 could be a mechanism to augment the levels of DAG or other lipid second messengers which participate in the relaying of the mitogenic signal to the nucleus.
GSK-3 GSK-3 is constitutively active in non-proliferating cells and has diverse substrates, including glycogen synthase, protein phosphatase 1, ATP citrate lyase, the R subunit of protein kinase A, c-Jun, c-Myc, c-Myb and CREB. GSK-3 inactivation by EGF or insulin treatment is mediated via the MAP kinase/p90 ribosomal S6 kinase pathway [50] [51] [52] [53] , and this inactivation of GSK-3 may be important in mitogenic signalling. Phosphorylation by GSK-3 is usually associated with inactivation of its substrates [54] . The function of CT phosphorylation by GSK-3 might be to inactivate CT during growth arrest. We found that CT was a substrate for GSK-3,i in vitro and mapped the site using chymotrypsin proteolysis to at least three C-terminal fragments differing in mass by 1-2 kDa. All three of these bands begin at Thr-226 and differ at their C-termini. Since the shortest fragment extending from Thr-226 to, most likely, Phe-334 (apparent mass, 16 kDa; actual mass, 13 kDa) was as intensely labelled as the largest (apparent mass, 19 kDa; actual mass, 16 kDa), this suggests that the sites targeted by GSK-3 lie in domain P between residues 314 and 334 (see Figure 7) .
Identification of the kinases that regulate CT activity will require an 'in vivo' approach in addition to the 'in vitro' approach taken here. This is an important task, as it will help to define the role of CT in signal transduction pathways involving the PC metabolic cycle. 
